The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | The potential of T-cell therapy for the treatment of fibrolamellar hepatocellular carcinoma
Marina Baretti, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses the potential of T-cell therapy in targeting cancer cells in fibrolamellar hepatocellular carcinoma (FLC) by specifically recognizing and attacking the fusion protein expressed by cancer cells, while also modulating the immune system to target the myeloid component of the tumor microenvironment (TME), a common mechanism of resistance to cancer treatments. This approach aims to enhance the effectiveness of immunotherapy. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, another promising approach will be T-cell therapy, with T-cells that specifically target this fusion that is only expressed by the cancer cell and that is not expressed by the normal cells. And perhaps an immune modulatory agent that can target the myeloid component in the tumor microenvironment because that seems also a mechanism of resistance, at least based on some of the results from our study as well...
You know, another promising approach will be T-cell therapy, with T-cells that specifically target this fusion that is only expressed by the cancer cell and that is not expressed by the normal cells. And perhaps an immune modulatory agent that can target the myeloid component in the tumor microenvironment because that seems also a mechanism of resistance, at least based on some of the results from our study as well.
Read more...
